Sugi Predict

Sugi Predict / Compounds / SCHEMBL20116639

SCHEMBL20116639

SCHEMBL20116639

COc1ccc(-c2nsc(C3CCN(C(=O)OC(C)(C)C)CC3)n2)cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 3/20 0.49
▸ PIK3CD O00329 2/20 0.49
▸ PIK3CA P42336 2/20 0.49
▸ PIK3CB P42338 2/20 0.49
▸ PIK3CG P48736 2/20 0.49
▸ MMP13 P45452 1/20 0.49
▸ HTT P42858 2/20 0.48
▸ SMPD3 Q9NY59 2/20 0.48
▸ PDE4A P27815 2/20 0.48
▸ PDE4C Q08493 2/20 0.48
▸ PDE4D Q08499 2/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ CFTR P13569 1/20 0.48
▸ TLR8 Q9NR97 1/20 0.47
▸ TLR7 Q9NYK1 1/20 0.47
▸ GPR119 Q8TDV5 4/20 0.47
▸ KDM4E B2RXH2 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ HPGD P15428 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20116206 0.83 HTT (0.50) PDE4BPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL30720990 0.83 HTT (0.50) PDE4BPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL20116960 0.81 GPR119 (0.43) HTTMEN1KMT2AGPR119KDM4E
SCHEMBL20116147 0.78 GPR119 (0.48) PIK3CAPIK3CGHTTGPR119
SCHEMBL20116563 0.77 KDM4E (0.62) PDE4BPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL30720970 0.77 KDM4E (0.62) PDE4BPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL24265188 0.76 PDE4B (0.50) PDE4BPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL20116850 0.76 GPR119 (0.43) PIK3CAHTTGPR119CHEK2
SCHEMBL30720958 0.76 GRM1 (0.48) PDE4BMMP13SMPD3CFTRTLR7
SCHEMBL20117184 0.76 GRM1 (0.48) PDE4BMMP13SMPD3CFTRTLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12275723-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2025-04-15 — — US disclosed
US-20240400546-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-12-05 — — US disclosed
US-20240300938-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-09-12 — — US disclosed
US-11970486-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-04-30 — — US disclosed
US-20240124435-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-04-18 — — US disclosed
CN-117777121-A Compounds and uses thereof 詹森药业有限公司 2024-03-29 — — CN disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 — — US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 — — US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 — — US disclosed
CN-110099898-B Compounds and uses thereof 优曼尼蒂治疗公司 2023-07-25 — — CN disclosed
EP-3700934-A1 COMPOUNDS AND USES THEREOF Yumanity Therapeutics, Inc. (US) 2020-09-02 — — EP disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 — — US disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 — — US disclosed
WO-2019209948-A9 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-01-02 — — WO disclosed
WO-2019209948-A9 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-01-02 — — WO disclosed
EP-3529245-A1 COMPOUNDS AND USES THEREOF Yumanity Therapeutics, Inc. (US) 2019-08-28 — — EP disclosed
WO-2019018795-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2019-01-24 — — WO disclosed
WO-2019018795-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2019-01-24 — — WO disclosed
WO-2018081167-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2018-05-03 — — WO disclosed
WO-2018081167-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2018-05-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124435-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 PDE4B 180/4885PIK3CD 3927/4885PIK3CA 3734/4885
US-20240300938-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 PDE4B 180/4885PIK3CD 3927/4885PIK3CA 3734/4885
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 PDE4B 180/4885PIK3CD 3927/4885PIK3CA 3734/4885
US-20240400546-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 PDE4B 180/4885PIK3CD 3927/4885PIK3CA 3734/4885
US-12275723-B2 Compounds and uses thereof NLN, ACHE, CLN6 PDE4B 180/4885PIK3CD 3927/4885PIK3CA 3734/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 PDE4B 180/4885PIK3CD 3927/4885PIK3CA 3734/4885
US-11970486-B2 Compounds and uses thereof NLN, ACHE, CLN6 PDE4B 180/4885PIK3CD 3927/4885PIK3CA 3734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.